KR102825098B1 - 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디 - Google Patents

수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디 Download PDF

Info

Publication number
KR102825098B1
KR102825098B1 KR1020207013387A KR20207013387A KR102825098B1 KR 102825098 B1 KR102825098 B1 KR 102825098B1 KR 1020207013387 A KR1020207013387 A KR 1020207013387A KR 20207013387 A KR20207013387 A KR 20207013387A KR 102825098 B1 KR102825098 B1 KR 102825098B1
Authority
KR
South Korea
Prior art keywords
glp
patient
peptibody
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013387A
Other languages
English (en)
Korean (ko)
Other versions
KR20200085763A (ko
Inventor
클락 팬
안젤라 노턴
베티나 스트랙-로그
클레멘트 올리비에
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20200085763A publication Critical patent/KR20200085763A/ko
Application granted granted Critical
Publication of KR102825098B1 publication Critical patent/KR102825098B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207013387A 2017-11-06 2018-11-05 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디 Active KR102825098B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06
PCT/US2018/059175 WO2019090209A1 (en) 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before during, or after surgery

Publications (2)

Publication Number Publication Date
KR20200085763A KR20200085763A (ko) 2020-07-15
KR102825098B1 true KR102825098B1 (ko) 2025-06-26

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013387A Active KR102825098B1 (ko) 2017-11-06 2018-11-05 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디

Country Status (14)

Country Link
US (1) US11660328B2 (enExample)
EP (1) EP3706774A4 (enExample)
JP (2) JP7296958B2 (enExample)
KR (1) KR102825098B1 (enExample)
CN (1) CN111629745A (enExample)
AR (1) AR113835A1 (enExample)
AU (1) AU2018360744A1 (enExample)
BR (1) BR112020008936A2 (enExample)
CA (1) CA3079523A1 (enExample)
IL (1) IL274098B2 (enExample)
MX (1) MX2020004620A (enExample)
TW (1) TW201922279A (enExample)
WO (1) WO2019090209A1 (enExample)
ZA (1) ZA202002080B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7249492B2 (ja) * 2017-08-22 2023-03-31 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用
US20210355187A1 (en) * 2018-10-24 2021-11-18 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
US20230129788A1 (en) * 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809318B1 (en) * 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US20090175795A1 (en) 2005-07-29 2009-07-09 Amprotein Corporation Chimeric therapeutic agents
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP5290177B2 (ja) * 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
PT2755675T (pt) 2011-09-12 2018-10-11 Amunix Operating Inc Composições de péptido semelhante a glucagão-2 e métodos para produzir e utilizar as mesmas
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
CN111629745A (zh) 2020-09-04
WO2019090209A1 (en) 2019-05-09
MX2020004620A (es) 2020-10-12
EP3706774A1 (en) 2020-09-16
CA3079523A1 (en) 2019-05-09
AU2018360744A1 (en) 2020-05-07
KR20200085763A (ko) 2020-07-15
RU2020118172A (ru) 2021-12-08
US20210169986A1 (en) 2021-06-10
TW201922279A (zh) 2019-06-16
IL274098B2 (en) 2024-12-01
JP2023107883A (ja) 2023-08-03
JP7752152B2 (ja) 2025-10-09
IL274098B1 (en) 2024-08-01
ZA202002080B (en) 2025-11-26
US11660328B2 (en) 2023-05-30
JP7296958B2 (ja) 2023-06-23
BR112020008936A2 (pt) 2020-10-20
EP3706774A4 (en) 2021-09-08
JP2021502389A (ja) 2021-01-28
IL274098A (en) 2020-06-30
AR113835A1 (es) 2020-06-17

Similar Documents

Publication Publication Date Title
KR102825098B1 (ko) 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디
ES2733220T3 (es) Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento
KR102088856B1 (ko) 지속형 인슐린 결합체의 액상 제제
RU2606840C2 (ru) Композиция для лечения диабета, содержащая конъюгат инсулина длительного действия и конъюгат инсулинотропного пептида длительного действия
EP2185178B1 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
Braga Emidio et al. Structure, function, and therapeutic potential of the trefoil factor family in the gastrointestinal tract
KR20110021758A (ko) 이형체-특이적 인슐린 유사체
KR20100020516A (ko) Ｇｌｐ-1-ｆｃ 융합 단백질 제제
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
US20180280474A1 (en) Treatment of bile acid disorders
RU2795594C2 (ru) Пептитело glp-2 для введения до, в течение или после хирургического вмешательства
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
CA3008392C (en) Ameliorating systemic sclerosis with death receptor agonists
WO2015057908A1 (en) Methods of treating diabetes and related disorders
WO2021263040A1 (en) Stable peptibody formulations
HK1258208B (en) Ameliorating systemic sclerosis with death receptor agonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000